<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Combined immunodeficiencies: Specific defects</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Combined immunodeficiencies: Specific defects</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Combined immunodeficiencies: Specific defects</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Heimall, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Luigi D Notarangelo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1643307369"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The combined immunodeficiency (CID) defects reviewed here include monogenic inborn errors of immunity (IEI; primary immunodeficiency [PID]) associated with severe T cell quantitative or functional defects but without other syndromic or nonimmunologic features [<a href="#rid1">1</a>]. Many of them can be sorted mechanistically, including impaired T cell receptor (TCR) signaling, cytokine signaling, cellular immunity by disruption of actin rearrangement, or cellular immunity by disruption of regulation and activity of critical transcription factors.</p><p>Some of the more common disorders are described in dedicated topic reviews; others are described in this topic or, if only reported in a few patients, in the table  (<a class="graphic graphic_table graphicRef139920" href="/z/d/graphic/139920.html" rel="external">table 1</a>). A separate topic gives a broad overview of the clinical presentation, diagnosis, and management of CID. (See  <a class="medical medical_review" href="/z/d/html/3935.html" rel="external">"Combined immunodeficiencies: An overview"</a>.)</p><p>CID that are discussed in greater detail separately include:</p><p class="bulletIndent1"><span class="glyph">●</span>CD40 and CD40 ligand deficiencies (see  <a class="medical medical_review" href="/z/d/html/13567.html" rel="external">"Hyperimmunoglobulin M syndromes"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD3 gamma-chain deficiency (see  <a class="medical medical_review" href="/z/d/html/3956.html" rel="external">"CD3/T cell receptor complex disorders causing immunodeficiency", section on 'CD3 deficiency'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serine threonine kinase 4 deficiency (see  <a class="medical medical_review" href="/z/d/html/3956.html" rel="external">"CD3/T cell receptor complex disorders causing immunodeficiency", section on 'STK4 deficiency'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interleukin (IL) 2-inducible T cell kinase (ITK) deficiency (see  <a class="medical medical_review" href="/z/d/html/3956.html" rel="external">"CD3/T cell receptor complex disorders causing immunodeficiency", section on 'ITK deficiency'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Zeta chain-associated protein (ZAP) 70 deficiency (see  <a class="medical medical_review" href="/z/d/html/3940.html" rel="external">"ZAP-70 deficiency"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Major histocompatibility complex (MHC) class I and II deficiencies (see  <a class="medical medical_review" href="/z/d/html/3956.html" rel="external">"CD3/T cell receptor complex disorders causing immunodeficiency", section on 'MHC (HLA) class I deficiency'</a> and  <a class="medical medical_review" href="/z/d/html/3956.html" rel="external">"CD3/T cell receptor complex disorders causing immunodeficiency", section on 'MHC (HLA) class II deficiency'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ras homolog gene family member H (RHOH) deficiency (see  <a class="medical medical_review" href="/z/d/html/3956.html" rel="external">"CD3/T cell receptor complex disorders causing immunodeficiency", section on 'RHOH deficiency'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TCR alpha subunit constant (TRAC) deficiency (see  <a class="medical medical_review" href="/z/d/html/3956.html" rel="external">"CD3/T cell receptor complex disorders causing immunodeficiency", section on 'TRAC deficiency'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocyte-specific protein-tyrosine kinase (p56lck) deficiency (see  <a class="medical medical_review" href="/z/d/html/3956.html" rel="external">"CD3/T cell receptor complex disorders causing immunodeficiency", section on 'Lck deficiency'</a>)</p><p></p><p>Syndromic immunodeficiencies are also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/3951.html" rel="external">"Syndromic immunodeficiencies"</a>.)</p><p class="headingAnchor" id="H3338397241"><span class="h1">DISORDERS OF T CELL RECEPTOR SIGNALING</span></p><p class="headingAnchor" id="H3989647523"><span class="h2">CD8 deficiency</span><span class="headingEndMark"> — </span>CD8 is a T cell receptor (TCR) accessory molecule that binds to class I major histocompatibility complex (MHC). CD8 is primarily expressed on cytotoxic T cells but is also found on natural killer (NK) cells. It plays an important role in the antigen-specific activation and function of cytotoxic T cells. (See  <a class="medical medical_review" href="/z/d/html/3956.html" rel="external">"CD3/T cell receptor complex disorders causing immunodeficiency"</a>.)</p><p>CD8 deficiency due to a homozygous pathogenic variant in the gene for the CD8 alpha chain (<em>CD8A</em>) on chromosome 2p12 (MIM #608957) was reported in three offspring of consanguineous parents [<a href="#rid2">2</a>]. Only one of them, a 25-year-old male, was symptomatic. He had recurrent sinopulmonary infections beginning at approximately age five years, which suggested a humoral deficiency. However, his immunoglobulin levels and specific antibody titers were normal. CD4+ T cell, B cell, and NK cell percentages and absolute counts were normal, but CD8+ T cells were completely absent. He had two younger sisters who also had absent CD8+ T cells but were asymptomatic at the time of the report. Genetic defects were not described in these patients. <em>CD8A </em>pathogenic variants were identified in several additional patients with variable disease severity (recurrent respiratory tract infections with or without pulmonary parenchymal damage) [<a href="#rid3">3,4</a>]. The differential diagnosis for this phenotype is defects of the ZAP-70 kinase, MHC class I expression, or CD8. (See  <a class="medical medical_review" href="/z/d/html/3940.html" rel="external">"ZAP-70 deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/3956.html" rel="external">"CD3/T cell receptor complex disorders causing immunodeficiency", section on 'MHC (HLA) class I deficiency'</a>.)</p><p>There are no published data regarding therapy for these patients. Management is directed toward infectious complications and may include <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement.</p><p class="headingAnchor" id="H3225316553"><span class="h2">ICOS and ICOSL deficiency</span><span class="headingEndMark"> — </span>The <em>ICOS </em>gene, located at chromosome 2q33.2, encodes inducible T cell costimulator, which is similar in structure to CD28 and cytotoxic T lymphocyte-associated 4 (CTLA4). As the name implies, this T cell surface marker is only expressed in activated T cells [<a href="#rid5">5</a>]. It is not constitutively expressed. It functions to induce interleukin (IL) 10 synthesis and also impacts follicular recruitment of activated CD4 cells, leading to germinal center defects when absent [<a href="#rid6">6</a>]. ICOS is important in the development of T helper type 1 (Th1), T helper type 2 (Th2), and T helper type 17 (Th17) based immunity [<a href="#rid7">7,8</a>]. ICOS ligand, encoded by the <em>ICOSL</em> gene on chromosome 21q22.3, is expressed on B cells and enhances germinal center interactions between follicular T cells and B cells. In the absence of ICOSL, the selection of high-affinity B cells within the germinal center is impaired.</p><p>Several case series of patients have been described [<a href="#rid9">9,10</a>]. Both <em>ICOS</em> and <em>ICOSL</em> deficiency are inherited in an autosomal recessive pattern. Patients develop clinical symptoms from infancy through adulthood. Patients with ICOS deficiency have demonstrated normal levels of T cells, B cells, and immunoglobulin levels but manifest with symptoms of recurrent infections, autoimmunity, gastroenteritis, and granulomas [<a href="#rid1">1,10</a>]. In contrast, patients with ICOSL<em> </em>deficiency have demonstrated lower T and B cells with lower immunoglobulin levels and clinically manifest with recurrent bacterial and viral infections, as well as neutropenia.</p><p class="headingAnchor" id="H2881419537"><span class="h1">DISORDERS OF CYTOKINE SIGNALING</span></p><p class="headingAnchor" id="H1895237847"><span class="h2">IL-21 and IL-21 receptor deficiencies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of IL-21</strong> – Interleukin (IL) 21 is a common gamma chain-related cytokine that signals primarily through the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. This cytokine plays a critical role in immune cell development, differentiation, proliferation, function, and survival. Deficiencies of IL-21 or its receptor (IL-21R) cause an immunodeficiency similar to common variable immunodeficiency (CVID) [<a href="#rid11">11-13</a>]. (See  <a class="medical medical_review" href="/z/d/html/16132.html" rel="external">"Common variable immunodeficiency in children"</a> and  <a class="medical medical_review" href="/z/d/html/3904.html" rel="external">"Pathogenesis of common variable immunodeficiency", section on 'Genetics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Most patients with IL-21R deficiency (MIM #615207) present in early childhood with recurrent sinopulmonary and gastrointestinal infections with both common and opportunistic organisms [<a href="#rid11">11,13-15</a>]. The most notable of these is cryptosporidial infections associated with chronic cholangitis, biliary fibrosis, liver disease, and chronic diarrhea. Fungal infections, lymphoproliferation, inflammatory skin disease, and anaphylaxis have also been reported. Another presented with recurrent sinopulmonary infections (recurrent otitis media at two years of age, severe interstitial pneumonia with acute respiratory distress syndrome at five years of age, and then <em>Pneumocystis jirovecii</em> pneumonia [PJP] with bronchiectasis at six years of age) but no liver or gastrointestinal disease [<a href="#rid16">16</a>]. A patient with IL-21 deficiency (MIM #615767) had recurrent sinopulmonary infections and very-early-onset inflammatory bowel disease (VEO-IBD) with chronic nonbloody diarrhea, failure to thrive, and recurrent aphthous stomatitis [<a href="#rid12">12</a>]. The child's two siblings also had early-onset IBD and died in infancy. (See  <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Very early-onset inflammatory bowel disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings</strong> – T, B, and natural killer (NK) cell numbers are normal in patients with IL-21R deficiency, but they have defects in B cell proliferation and immunoglobulin class switching, decreased T cell proliferation to recall antigens and cytokine production, and variable impairment of NK cell cytotoxicity [<a href="#rid11">11,13</a>]. Immunoglobulin E (IgE) levels are elevated, specific antibody responses to immunizations are reduced, and some patients have decreased immunoglobulin G (IgG) levels. Elevated IgE, decreased IgG, and reduced antibody responses to immunizations were also seen in the patient with IL-21 deficiency [<a href="#rid12">12</a>]. In addition, B cells were decreased, with a reduction in marginal zone and class-switch B cells but an increase in transitional B cells, and T cell proliferation was impaired.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– Four of the seven patients with IL-21R deficiency in one report underwent hematopoietic cell transplantation (HCT), but three died due to complications [<a href="#rid13">13</a>]. The remaining patients were receiving <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement therapy. Another patient with IL-21R deficiency underwent successful HCT after developing lymphoma [<a href="#rid14">14</a>]. One patient with IL-21 deficiency was receiving prophylactic antibiotics in addition to immune globulin replacement therapy and treatment for IBD [<a href="#rid12">12</a>]. Administration of recombinant IL-21 is a potential therapeutic option for this patient.</p><p></p><p class="headingAnchor" id="H956215244"><span class="h1">DISORDERS INVOLVING THE ACTIN CYTOSKELETON</span></p><p class="headingAnchor" id="H1862391614"><span class="h2">DOCK2 deficiency</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – Dedicator of cytokinesis 2 (DOCK2) deficiency is due to biallelic (homozygous or compound heterozygous) pathogenic variants in <em>DOCK2</em> on chromosome 5q35 (MIM #616533). DOCK2 deficiency was first identified through whole exome sequencing in five unrelated patients with early-onset invasive bacterial and viral infections, lymphopenia, and defective T, B, and natural killer (NK) cell responses [<a href="#rid17">17</a>]. The pathogenic variants included missense and nonsense point mutations, as well as insertions leading to frameshift and premature termination. Four siblings with leaky severe combined immunodeficiency (SCID) or Omenn syndrome due to a homozygous splice-site mutation in <em>DOCK2</em> resulting in complete loss of DOCK2 expression were also identified [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/3935.html" rel="external">"Combined immunodeficiencies: An overview", section on 'Genotypes and immunophenotype severity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis and laboratory findings</strong> – DOCK2 is expressed in peripheral blood leukocytes, as well as in the thymus, spleen, and liver. DOCK2 activates Ras-related C3 botulinum toxin substrate 1 (RAC1; a small GTP-binding protein), which is involved in actin polymerization and cell proliferation. DOCK2 deficiency results in impaired RAC1 activation, with defective actin polymerization and chemokine-mediated migration in T, B, and NK cells; impaired NK cell degranulation after stimulation; decreased circulating natural killer T (NKT) cells; diminished interferon (IFN) alpha, beta, and lambda production in peripheral blood mononuclear cells in response to viral infections; and enhanced levels of viral replication and virus-induced cell death in fibroblasts. Partial impairment of cytoskeletal rearrangement and production of reactive oxygen species is also seen, leading to symptoms of dysfunctional neutrophils that are also observed in affected patients [<a href="#rid18">18</a>]. Mitochondrial dysfunction in T cells contributes to T cell lymphopenia [<a href="#rid19">19</a>]. Elevated serum immunoglobulin M (IgM) was reported in one patient [<a href="#rid20">20</a>] and elevated IgE with slightly low IgM in another [<a href="#rid21">21</a>]. Reduced T cell receptor excision circle (TREC) levels at birth was documented in one patient [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Most patients presented in the first three to four months of life with recurrent viral and bacterial respiratory tract infections [<a href="#rid17">17</a>]. Other early findings included chronic or recurrent diarrhea and growth failure. Disseminated vaccine-strain varicella, local lesion at the site of Bacillus Calmette-Guérin (BCG) vaccination, oral moniliasis, and severe infections with <em>Mycobacterium avium</em>, human herpesvirus-6, mumps, parainfluenza virus type 3, adenovirus, cytomegalovirus (CMV), and <em>Klebsiella pneumoniae</em> were also reported. Additional documented clinical features included thrombocytopenia, hepatomegaly, colitis, and rectal fistula.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment, complications, and prognosis</strong> – Two of the initial identified patients died in early childhood. The other three patients underwent successful hematopoietic cell transplantation (HCT). In vitro studies showed normalization of fibroblast defects after treatment with IFN-alfa-2b or lentiviral-mediated expression of wild-type DOCK2. Another patient developed hemophagocytic lymphohistiocytosis (HLH) due to Epstein-Barr virus (EBV) infection after HCT [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H2396844120"><span class="h2">DOCK8 deficiency</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – Over 200 patients have been identified with pathogenic variants in the dedicator of cytokinesis 8 (<em>DOCK8</em>) gene that is predominantly expressed in white blood cells [<a href="#rid23">23-33</a>]. Most of these mutations are loss-of-function (LOF) homozygous or compound heterozygous point mutations, although some deletions have been identified. DOCK8 deficiency (MIM #243700) was initially classified as type 2 hyperimmunoglobulin E syndrome (HIES) with autosomal recessive inheritance, although approximately 40 percent of patients do not have HIES [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/3960.html" rel="external">"Autosomal dominant hyperimmunoglobulin E syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The susceptibility to cutaneous infections in patients with DOCK8 deficiency may be due to an inability of CD8 cells to effectively enter into the skin [<a href="#rid34">34</a>]. DOCK8 function is required for proper cytoskeletal organization, an integral part of leukocyte activation. As a result of impaired cytoskeletal function in DOCK8 deficiency, CD8 T cells (and NK cells) cannot migrate into tissues with dense collagen structure, such as the skin. Instead, they die by a particular form of apoptosis that has been named "cytothripsis" and cannot populate the skin with resident memory CD8 cells [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings</strong> – Most patients have low absolute lymphocyte counts, with low T cells. B and NK cells are also low in many patients. NK cell function [<a href="#rid35">35</a>], CD8 T cell survival and function [<a href="#rid36">36</a>], peripheral B cell tolerance [<a href="#rid37">37</a>], and regulatory T (Treg) cell function are impaired. Most patients also have eosinophilia and elevated IgE. IgM levels are low, but many patients have increased IgG levels. IgG antibody responses to bacterial and viral antigens are variable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Common clinical features include recurrent respiratory tract infections (otitis media, sinusitis, pneumonia), bronchiectasis, extensive cutaneous viral infections (herpes simplex virus, herpes zoster, molluscum contagiosum, human papillomavirus [HPV]), <em>Staphylococcus aureus</em> skin infections, mucocutaneous candidiasis, atopic disease (atopic dermatitis, severe food and environmental allergies, asthma), failure to thrive, chronic diarrhea, hepatic disorders (sclerosing cholangitis, hepatitis), cancer (vulvar, facial, and anal squamous cell dysplasia and carcinomas, T cell lymphoma-leukemia, and Burkitt and non-Hodgkin lymphomas), and autism spectrum disorders [<a href="#rid23">23-25,27,29,38-42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis (STAT3 LOF HIES and severe atopic dermatitis)</strong> – Almost all of the features associated with autosomal dominant signal transducer and activator of transcription (STAT) 3 LOF HIES (type 1) can also be seen in patients with DOCK8 deficiency. Thus, it can be difficult to assign patients to one category or another based upon clinical features alone. However, there are five clinical features that have good predictive value for distinguishing the two groups: Parenchymal lung abnormalities, retained primary teeth, and fractures with minimal trauma are seen more often with STAT3 defects, while frequent upper respiratory infections and eosinophilia are more prominent in patients with DOCK8 deficiency [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">Mucocutaneous candidiasis and herpes infection are common in DOCK8 deficiency but infrequently seen in severe atopic dermatitis [<a href="#rid43">43</a>]. However, they otherwise have overlapping features that can make it difficult to differentiate between the two disorders without specialized diagnostic testing (eg, immunoblot, flow cytometry [<a href="#rid44">44</a>], and deoxyribonucleic acid [DNA] sequencing). The profile of low percentages of CD3+, CD4+, and naïve CD8+ T cells along with a normal total B cell percentage but low percentages of switched memory B cells (IgM-IgD-CD27+) is strongly associated with DOCK8 deficiency (odds ratio 26.3, 95% CI 9.4-73.4, in favor of a DOCK8 deficiency diagnosis versus severe atopic dermatitis) [<a href="#rid45">45</a>]. These lymphocyte biomarkers are a potential tool to screen patients with severe eczema for DOCK8 deficiency to determine which patients should have more extensive diagnostic testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Somatic reversion</strong> – In one series of 34 patients with germline <em>DOCK8</em> pathogenic variants, one-half had variable degrees of somatic reversion with restoration of DOCK8 expression mainly within antigen experience T cells or NK cells [<a href="#rid46">46</a>]. These patients were older and had less severe allergic disease. However, they continued to have recurrent cutaneous and sinopulmonary infections and still required HCT for a cure. In another series of three patients, somatic reversion occurred in multiple lymphocyte subsets with complete resolution of clinical manifestations of the disease [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Over 100 patients with DOCK8 deficiency have received HCT [<a href="#rid29">29,34,40-42,48-56</a>]. Survival has been excellent with generally rapid and complete immune reconstitution and resolution of infections and other clinical features. Several patients with severe herpes or papilloma virus skin infections refractory to antiviral therapy have responded to systemic IFN-alfa-2b [<a href="#rid57">57-59</a>]. <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">Dupilumab</a>, an IL-4 receptor antagonist, has been used successfully as bridge therapy to treat the severe atopic dermatitis before HCT [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/3941.html" rel="external">"Hematopoietic cell transplantation for non-SCID inborn errors of immunity", section on 'DOCK8 deficiency'</a>.)</p><p></p><p class="headingAnchor" id="H2140527905"><span class="h2">FCHO1 deficiency</span><span class="headingEndMark"> — </span>The Fer/Cip4 homology (FCH) and mu domain-containing endocytic adaptor 1 (<em>FCHO1</em>) gene, located at chromosome 11p13.11, encodes the FCHO1 protein, which is involved in the ability to make clathrin-coated pits that are critically important for endocytosis. This inborn error of immunity (IEI) is inherited in an autosomal recessive pattern. Affected patients have low T cells, with poor proliferation and increased activation-induced T cell death, while B cell number and function are variable. Clinically, the patients described have experienced recurrent infections and failure to thrive. Additionally, several patients have been diagnosed with B cell lymphoma. Five patients have had clinical improvement following hematopoietic cell transplantation [<a href="#rid1">1,61,62</a>].</p><p class="headingAnchor" id="H1753162207"><span class="h2">Moesin deficiency</span><span class="headingEndMark"> — </span>The <em>MSN</em> gene, located on chromosome Xq12, encodes moesin protein, which is part of the ezrin-radixin-moesin (ERM) family of proteins that function together to stabilize the submembranous cytoskeleton. Moesin is particularly critical in the development of filopodia and cell membrane protrusions that are needed for cell movement and communication between cells. The role of moesin is essential for the development of a functional immunologic synapse.</p><p>Several patients with hemizygous pathologic variants in <em>MSN</em> have been described (MIM 300988) and at least two of whom were identified via TREC-based SCID newborn screening [<a href="#rid63">63-66</a>]. Clinical features include recurrent infections of the respiratory, gastrointestinal, and genitourinary tracts with bacterial, as well as varicella and newborn CMV infections. Both T cells and B cells have are present in lower-than-normal numbers, with defective proliferation and migration. Specifically, both CD4+ and CD8+ are low, with lower-than-expected naïve T cell populations (CD45RA+CD32+CD4+ and CD45RA+CCR7+CD8+) for age. Neutropenia is variably present. Immunoglobulin levels can decline with time. In some cases, the clinical presentation may resemble SCID, and HCT has been described in these patients [<a href="#rid65">65</a>].</p><p>The severity of the phenotype is variable and may include autoimmune features such as antiphospholipid syndrome, Hashimoto thyroiditis, leg ulcers, and juvenile tooth loss [<a href="#rid66">66</a>]. Therapies can be targeted to autoimmune symptoms; immunologic supportive therapies may not be required.</p><p class="headingAnchor" id="H2679218111"><span class="h1">DEFECTS OF TRANSCRIPTION FACTORS CRITICAL TO T CELL FUNCTION</span></p><p class="headingAnchor" id="H344066837"><span class="h2">Disorders of the CBM signalosome complex</span><span class="headingEndMark"> — </span>The CBM signalosome complex comprises the intracellular molecules caspase recruitment domain-containing protein 11 (CARD11; ie, CARMA1), B cell chronic lymphocytic leukemia (CLL)/lymphoma 10 (BCL10), and mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1). The CBM complex functions to regulate the activity of nuclear factor kappa B (NFkB) signaling in T and B cells after the stimulation of the T cell receptor (TCR) or B cell receptor. CARD11 is a membrane-associated protein, which, when phosphorylated, links to BCL10. BCL10 and MALT1 are constitutively linked. The formation of the CBM allows for regulation of I-kappa-B kinase (IKK) mediated NFkB activation [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H4020721074"><span class="h3">BCL10 deficiency</span><span class="headingEndMark"> — </span>Autosomal recessive, complete B cell chronic lymphocytic leukemia (CLL)/lymphoma 10 (BCL10) deficiency (MIM #616098) was reported in a child with a history of recurrent and severe respiratory tract and gastrointestinal infections of viral and bacterial origin, leading to death in the fourth year of life [<a href="#rid68">68</a>]. A homozygous <em>BCL10</em> splice-site mutation was shown to abrogate protein expression. Analysis of lymphocyte subsets demonstrated a marked decrease of memory T and B cells and regulatory T (Treg) cells, and in vitro proliferative response to CD3/CD28 stimulation was absent. The defect was not confined to adaptive immunity; the patient's fibroblasts failed to respond to Toll-like receptor (TLR) 4, TLR2/6, and dectin-1 agonists.</p><p>A second patient homozygous for a different pathogenic variant also had recurrent respiratory infections and similar laboratory findings but did not have gastrointestinal disease [<a href="#rid69">69</a>]. A third patient, also with a novel pathogenic variant, had decreased natural killer (NK), gamma-delta T, and T follicular helper (Tfh) cells in addition to previously reported near absence of Treg cells and memory B and T cells and was cured with hematopoietic cell transplantation (HCT) [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H1322936468"><span class="h3">CARD11 deficiency</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of CARD11</strong> – Caspase recruitment domain-containing protein 11 (CARD11) is a member of the membrane-associated guanylate kinase (MAGUK) family. It plays a role in differentiation of immunologic and neuronal tissues and is involved in activation of the NFkB pathway [<a href="#rid71">71-73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal recessive LOF CARD11 deficiency</strong> – CARD11 deficiency (MIM #615206) due to a homozygous mutation resulting in autosomal recessive loss of function (LOF) was reported in a 13-month-old girl with consanguineous parents [<a href="#rid74">74</a>]. She presented with <em>Pneumocystis jirovecii</em> pneumonia (PJP) and hypogammaglobulinemia. She had an older sister who had failed to thrive and died at three months of age from progressive respiratory failure. An older brother had meningitis and recurrent pneumonias by 6 months of age and died at 15 months of age after he developed a high fever and progressive respiratory distress in the setting of panhypogammaglobulinemia. Several other patients have presented with PJP or viral pneumonia in infancy [<a href="#rid67">67,75-77</a>]. Two of these patients had severe inflammatory gastrointestinal disease, and another had severe eczema [<a href="#rid77">77</a>]. Recurrent sinopulmonary bacterial infections are also reported.</p><p></p><p class="bulletIndent1">All reported patients with this deficiency had hypogammaglobulinemia (one went from isolated reduced IgG levels to panhypogammaglobulinemia over a three-month period) [<a href="#rid67">67,74-77</a>]. Total numbers of CD19+ B cells and CD4+ and CD8+ T cells were normal, but B cell differentiation was blocked at the late transitional stage, and regulatory, effector memory, follicular helper, and terminally differentiated T cell counts were reduced. Activation of the NFkB pathway was abrogated, and upregulation of OX40, an inducible T cell costimulatory, was impaired. Lymphocyte proliferation to T cell mitogens was impaired, but proliferation to a B cell mitogen was nearly normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dominant-negative LOF CARD11 deficiency</strong> – A heterozygous, dominant-negative <em>CARD11</em> mutation (R30W protein defect with loss-of-function) was reported in four affected members from a single family [<a href="#rid78">78,79</a>]. Patients manifested recurrent respiratory tract infections, asthma, and atopic dermatitis since childhood. Immunologic evaluation showed a normal T cell count but a skewed T cell repertoire and reduced in vitro T cell proliferation to mitogens and antigens. Immunoglobulin levels were low or borderline low in two patients and normal in the remaining two.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overlapping features</strong> – Severe atopic disease, particularly atopic dermatitis (90 percent of patients), and eosinophilia (80 percent of patients) is a unifying feature of patients with either autosomal recessive inherited LOF or dominant-negative variants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Described management is generally supportive, with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement due to poor antibody function and PJP prophylaxis. Due to severe atopy, several of the described patients required systemic immunomodulatory therapies including glucocorticoids and/or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. At least four patients with autosomal recessive LOF CARD11 deficiency have successfully undergone HCT [<a href="#rid74">74,75,77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other CARD11 defects</strong> – A CARD11 gain-of-function that leads to a humoral immunodeficiency is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3914.html" rel="external">"Primary humoral immunodeficiencies: An overview", section on 'Isotype, light chain, or functional deficiencies with generally normal numbers of B cells'</a>.)</p><p></p><p class="headingAnchor" id="H1614007852"><span class="h3">MALT1 deficiency</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of MALT1</strong> – The mucosa-associated lymphoid tissue lymphoma translocation gene 1 (<em>MALT1</em>) encodes a caspase-like cysteine protease that is part of a signalosome complex essential for NFkB activation [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and clinical manifestations</strong> – MALT1 deficiency (MIM #615468) due to a homozygous mutation was first reported in a 15-year-old girl and 13- and 7-year-old siblings, both with consanguineous parents [<a href="#rid80">80,81</a>]. Clinical presentations included a longstanding history of failure to thrive, severe eczema, recurrent bacterial and viral skin and lung infections with resultant chronic inflammatory lung disease and bronchiectasis, meningitis, inflammatory gastrointestinal disease, long bone fractures, recurrent production of granulation tissue, and severe periodontal disease. The 13-year-old girl and 7-year-old boy had persistent infections and died of respiratory failure. MALT1 deficiency was also reported in a male infant who presented with generalized skin rash, intestinal inflammation, and persistent cytomegalovirus (CMV) infection [<a href="#rid82">82</a>]. This patient had normal T cell receptor excision circle (TREC) levels at birth. Other patients have had an immunodeficiency, polyendocrinopathy, and enteropathy X-linked (IPEX) like [<a href="#rid83">83</a>] or Netherton/Omenn syndrome-like picture [<a href="#rid84">84</a>], and autoimmunity is common [<a href="#rid85">85,86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings</strong> – In the first reported patients, lymphocyte numbers were normal, with normal T and NK cell numbers. T cell proliferation to mitogens and TCR-mediated activation of NFkB were absent. IgG, immunoglobulin A (IgA), and IgM levels and production of protective antibody titers were normal. Phenotypic variability has been observed in the B cell compartment. The B cell count was markedly reduced in one patient but normal in another. Likewise, serum IgE was chronically elevated in one patent and normal in another. Other patients have had lymphocytosis, low to normal immunoglobulin levels, low T helper type 17 (Th17) cells, absent Treg cells, variable proliferative response to mitogens, and an abnormal TCR gamma chain repertoire [<a href="#rid83">83</a>]. Eosinophilia is common [<a href="#rid86">86</a>]. Progressive depletion of B cells was also reported [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Several patients were successfully treated with HCT [<a href="#rid83">83,86,88</a>].</p><p></p><p class="headingAnchor" id="H298270434"><span class="h2">c-Rel deficiency</span><span class="headingEndMark"> — </span>c-Rel deficiency is inherited in an autosomal recessive fashion due to pathologic variants in the REL proto-oncogene, NFkB subunit (<em>REL</em>) gene located on chromosome 2p16.1 and has been described in two kindreds. This gene encodes c-Rel, a transcription factor that is part of the NFkB signaling complex. c-Rel is critical to the development of several lymphocyte subsets and functional T and B cells due to deleterious impacts on the ability to produce interleukin (IL) 2, IL-12, and interferon (IFN) gamma [<a href="#rid1">1,89,90</a>]. NK cell cytotoxic function also is impaired [<a href="#rid91">91</a>]. Affected patients have normal to elevated overall numbers of T cells, with reduced proportions of memory CD4 cells and impaired proliferative capacity. B cells may be reduced in number with a predominantly naïve phenotype, impaired proliferation, and low immunoglobulin production, including a poor ability to make specific antibody to vaccine challenge. NK cell populations are also reduced. Clinically, patients have recurrent bacterial, mycobacterial, <em>Salmonella</em>, and opportunistic infections. Management is supportive, with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement therapy and antimicrobial prophylaxis.</p><p class="headingAnchor" id="H273294060"><span class="h2">Ikaros protein family deficiencies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathogenesis</strong> – The Ikaros family of proteins includes Ikaros, Helios, Aiolos, Eos, and Pegasus. The Ikaros family zinc finger 1 (<em>IKZF1</em>) gene, located at chromosome 7p12.2, encodes the Ikaros protein, a zinc finger transcription factor that is critical to lymphocyte development. The Ikaros family zinc finger 2 (<em>IKZF2)</em> gene, located at chromosome 2q34, encodes the Helios protein, a member of the Ikaros family of transcription factors that mediates protein dimerization (OMIM 606234). The Ikaros family zinc finger 3 (<em>IKZF3)</em> gene, located at chromosome 17q17, encodes the Aiolos protein, a hematopoietic transcription factor critical to lymphoid cell differentiation (OMIM 606221, 619437).</p><p></p><p class="bulletIndent1">The proteins mediate DNA binding through the N-terminus zinc finger domain and multimerization via the C-terminus zinc finger domain. More than 30 pathologic variants have been identified, and nearly half impact the DNA-binding domain. Ikaros deficiency is associated with the following molecular mechanisms: dominant-negative, LOF, haploinsufficiency, and defective dimerization. Autosomal dominant haploinsufficiency of Ikaros is associated with a common variable immunodeficiency (CVID) phenotype. Of note, gain-of-function in Ikaros has also been described in a limited number of patients and is categorized by the International Union of Immunological Societies (IUIS) to be within the group of Treg cell defects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of Ikaros deficiency</strong> – Patients with Ikaros deficiency due to LOF as well as autosomal dominant-negative defects have been described to have early-onset CID disease starting in the first year of life, with recurrent sinopulmonary infections and pneumocystis, although dominant-negative variants seem to be the most severe [<a href="#rid92">92</a>]. The dominant-negative variant effects most commonly impact the amino acid at position 159 within the DNA binding domain. The clinical laboratory phenotype in these patients manifests with an absence of memory B cells and little to no immunoglobulin production. The T cell immunophenotype is variable across reports, with some reporting absence of memory T cells and others with skewing of CD8+ T cells towards a naïve phenotype, while CD4+ skew towards a memory phenotype. Reduced numbers of neutrophils have also been described. Additionally, autoimmune features, particularly immune thrombocytopenia (ITP), are frequently seen, and B cell acute lymphoblastic leukemia (ALL) has also been described in a number of these patients. Management included <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement therapy and close monitoring for development of autoimmune, lymphoproliferative, and malignant complications. In patients with the N195 dominant-negative defects as well as patients with B cell ALL and somatic or germline <em>IKZF1</em> deletions, HCT was successful in correcting the immune dysfunction and improving survival in those with B cell ALL [<a href="#rid93">93-95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of Helios deficiency</strong> – Defects in Helios lead to abnormalities in Tfh cell, Treg cell, and NK cell physiology [<a href="#rid1">1,96-99</a>]. Affected patients with pathologic variants in either an autosomal dominant or autosomal recessive pattern have been described, and their clinical laboratory phenotype includes increased numbers of activated T cells, reduced memory B cells, and lower-than-expected immunoglobulin levels. Symptoms included features of both immunodeficiency and immunodysregulation. Infections included recurrent upper respiratory tract infections, pneumonia, and thrush. Symptoms of immunodysregulation included lymphoproliferation, lymphoma, oral ulcers, autoimmune cytopenias, hemophagocytic lymphohistiocytosis (HLH), and lupus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of Aiolos deficiency</strong> – An autosomal dominant missense variant in the DNA binding domain of <em>IKZF3</em> in patients from a single kindred manifests with increased Epstein-Barr virus (EBV) susceptibility leading to HLH and lymphoma. Laboratory abnormalities were noted in the CD4 population being skewed toward naïve T cells, in addition to an overall reduction in the number of circulating B cells [<a href="#rid100">100</a>]. In another kindred, several affected patients were also noted to have hypogammaglobulinemia and PJP [<a href="#rid101">101</a>].</p><p></p><p class="headingAnchor" id="H4025874427"><span class="h2">IKBKB deficiency</span><span class="headingEndMark"> — </span>I-kappa-B kinase (IKK) beta chain (IKBKB, also known as I-kappa-B kinase 2 [IKK2]) activates transcription factor NFkB, which results in activation of genes involved in inflammatory and other immune responses.</p><p>A series of patients from Canada who were of Northern Cree ancestry were found to have IKBKB deficiency (MIM #615592) due to homozygous null mutations [<a href="#rid102">102</a>]. These patients presented in early infancy with oral candidiasis. They went on to develop more severe infections in the first year of life, including parainfluenza pneumonia and bacterial sepsis (<em>Escherichia coli</em>, <em>Listeria</em>, <em>Serratia</em>, <em>Klebsiella</em>). One patient also had a nontuberculous mycobacterial infection. Another series of four patients from two consanguineous families in Qatar were identified with a homozygous nonsense mutation in <em>IKBKB</em> and recurrent viral, bacterial, and fungal infections [<a href="#rid103">103</a>]. Four children from two related Saudi families also had a novel homozygous nonsense pathogenic variant and presented with delayed umbilical cord separation in addition to severe infections [<a href="#rid104">104</a>]. The largest series of patients reported includes 16 subjects [<a href="#rid105">105</a>]. Bacterial, fungal, mycobacterial, and viral infections were present since early in life and were associated with failure to thrive. Bacterial and mycobacterial meningitis or brain abscesses were documented in six patients. Disseminated Bacillus Calmette-Guérin (BCG) infection was observed in all four infants who received BCG immunization at birth. One patient successfully underwent HCT without conditioning from a fully matched sibling donor [<a href="#rid104">104</a>]. Eight patients in the series discussed above also underwent HCT, but only three survived [<a href="#rid105">105</a>].</p><p class="headingAnchor" id="H713393327"><span class="h2">NIK deficiency</span><span class="headingEndMark"> — </span>The mitogen-activated protein kinase kinase 14 (<em>MAP3K14</em>) gene, located at chromosome 17q21.31, encodes the NFkB-inducing kinase (NIK) protein, a participant in the NFkB signaling pathway. In two reported patients, loss of NIK activity was associated with impaired activation of canonical and noncanonical NFkB signaling [<a href="#rid106">106</a>]. These patients demonstrated low B cell counts, with decreased switched memory B cells and poor production of immunoglobulin. While overall T cell counts were normal, the expression of IL7R on CD8+ cells was impaired, and the proliferative response to recall antigens was also lower than expected. Finally, NK cell counts were also low. Clinically, these patients presented with symptoms of infection including CMV, cryptosporidium, BCGosis, candidiasis, and recurrent bacterial and viral respiratory tract infections. Both patients were treated with HCT, but only one survived. Of note, the patient who did not survive was first treated with an unconditioned transplant followed by a second transplant.</p><p class="headingAnchor" id="H3842408215"><span class="h1">DEFECTS IN OTHER PATHWAYS CRITICAL TO T CELL DEVELOPMENT AND FUNCTION</span></p><p class="headingAnchor" id="H2304107430"><span class="h2">Polymerase delta deficiency</span><span class="headingEndMark"> — </span>Polymerase delta deficiency is associated with defects in the DNA polymerase delta 1, catalytic subunit (<em>POLD1</em>) and<em> </em>DNA polymerase delta 2, accessory subunit (<em>POLD2</em>) genes, located on chromosomes 19q13.33 and 7p13, respectively. These genes encode proteins that are components of the polymerase delta complex, critical to DNA repair. POLD1 protein is the catalytic component of the complex and supports synthesis of the lagging DNA strand, while POLD2 is an accessory subunit, involved in regulation of the polymerase delta complex activity and regulation of the cell cycle. Biallelic pathologic variants in both of these genes demonstrating an autosomal recessive mode of inheritance have been described in association with CID [<a href="#rid107">107,108</a>]. In addition, at least one patient with POLD1-associated immunodeficiency was identified via T cell receptor excision circle (TREC) based severe combined immunodeficiency (SCID) newborn screening [<a href="#rid109">109</a>].</p><p>Described patients suffered from recurrent bacterial and viral infections, including recurrent respiratory infections, persistent molluscum, warts, and skin abscesses. In addition, severe neurologic impairments and growth deficiency have been described [<a href="#rid107">107,108</a>]. Patients were found to have reduced T, B, and natural killer (NK) cell populations. T cells were skewed toward a memory phenotype, with expansion of T effector memory CD45RA+(T<sub>EMRA</sub>) CD4+CD8+ cells increased in some patients. A restricted T cell receptor (TCR) variable beta chain (Vbeta) repertoire and decreased proliferative capacity have also been described. B cells, although reduced in number, appear able to develop into class-switched memory cells. Despite this, lower-than-normal immunoglobulin levels have been noted in affected patients. All described patients have been managed supportively with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement therapy as well as antibacterial and antifungal prophylaxis.</p><p class="headingAnchor" id="H1843117840"><span class="h2">Transferrin receptor 1 defect</span><span class="headingEndMark"> — </span>The transferrin receptor 1 (TfR1, also CD71), encoded by the gene <em>TFRC</em>, is involved in the cellular uptake of iron. A missense mutation that disrupts the TfR1 internalization motif results in defective receptor endocytosis and markedly increased cell surface expression of TfR1. Patients homozygous for this mutation (MIM #616740) have severe, recurrent childhood infections, chronic diarrhea, and failure to thrive [<a href="#rid110">110,111</a>]. Less common findings included skin abscesses, developmental delay, optic nerve atrophy, goiter, vitiligo, conjunctivitis, and hemophagocytic lymphohistiocytosis (HLH) like features. Laboratory findings include hypo- or agammaglobulinemia; normal T and B cell counts but a decreased percentage of memory B cells and defective T cell proliferation to stimulation; and intermittent neutropenia and thrombocytopenia. In addition, patients have mild anemia resistant to iron supplementation. Six of 15 patients in one series had died, and eight had undergone hematopoietic cell transplantation (HCT) [<a href="#rid110">110,112</a>]. In another series of eight patients, two received HCT, five were on prophylactic treatment, and one had died [<a href="#rid111">111</a>].</p><p class="headingAnchor" id="H1917284473"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H3656783994"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – The combined immunodeficiency (CID) defects reviewed in this topic include monogenic inborn errors of immunity (IEI) associated with severe T cell quantitative or functional defects but without other syndromic or nonimmunologic features  (<a class="graphic graphic_table graphicRef139920" href="/z/d/graphic/139920.html" rel="external">table 1</a>). These disorders can be grouped based upon the mechanistic process affected by the underlying defect, including impaired T cell receptor (TCR) signaling, cytokine signaling, cellular immunity by disruption of actin rearrangement, and cellular immunity by disruption of regulation and activity of critical transcription factors. (See  <a class="medical medical_review" href="/z/d/html/3935.html" rel="external">"Combined immunodeficiencies: An overview"</a> and <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disorders of</strong> <strong>T cell receptor signaling</strong> – Many of the CID involve impaired T cell receptor (TCR) signaling. These include CD3, which is important in transducing the signal that initiates T cell activation and differentiation; class I or II major histocompatibility complex (MHC I or MHC II) molecules, which function to distinguish self from non-self and are involved in antigen processing and presentation; and CD8, which is a TCR accessory molecule that binds to MHC I and plays an important role in the antigen-specific activation and function of cytotoxic T cells. Management is directed toward infectious complications and may include <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement. Hematopoietic cell transplantation (HCT) can be curative, but experience is limited. (See  <a class="medical medical_review" href="/z/d/html/3956.html" rel="external">"CD3/T cell receptor complex disorders causing immunodeficiency"</a> and <a class="local">'Disorders of T cell receptor signaling'</a> above and  <a class="medical medical_review" href="/z/d/html/3941.html" rel="external">"Hematopoietic cell transplantation for non-SCID inborn errors of immunity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disorders of cytokine signaling</strong> – Interleukin (IL) 21 is a common gamma chain-related cytokine that plays a critical role in immune cell development, differentiation, proliferation, function, and survival. Deficiencies of IL-21 or its receptor (IL-21R) cause an immunodeficiency similar to common variable immunodeficiency (CVID). (See <a class="local">'Disorders of cytokine signaling'</a> above and  <a class="medical medical_review" href="/z/d/html/16132.html" rel="external">"Common variable immunodeficiency in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disorders involving the actin cytoskeleton</strong> – Dedicator of cytokinesis (DOCK) 2 and 8 function is required for proper cytoskeletal organization, an integral part of leukocyte activation. Common clinical features include recurrent viral and bacterial respiratory tract infections, chronic diarrhea, and growth failure. Patients with DOCK8 deficiency also have extensive atopic disease. Patients commonly undergo HCT. (See <a class="local">'Disorders involving the actin cytoskeleton'</a> above and  <a class="medical medical_review" href="/z/d/html/3941.html" rel="external">"Hematopoietic cell transplantation for non-SCID inborn errors of immunity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defects of transcription factors critical to T cell function</strong> – Caspase recruitment domain-containing protein 11 (CARD11), B cell chronic lymphocytic leukemia/lymphoma 10 (BCL10), and mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) comprise the CBM signalosome complex that is a key modulator of lymphocyte signaling through several pathways. The Ikaros family of proteins are critical to lymphocyte differentiation. Patients with defects in these and other transcription factors can present with severe atopic disease, malignancy, autoimmunity, and inflammatory disease in addition to immunodeficiency, depending upon the specific defect. Management is primarily supportive, with <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement therapy and antimicrobial prophylaxis. HCT has been performed, with mixed results. (See <a class="local">'Defects of transcription factors critical to T cell function'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473.</a></li><li><a class="nounderline abstract_t">de la Calle-Martin O, Hernandez M, Ordi J, et al. Familial CD8 deficiency due to a mutation in the CD8 alpha gene. J Clin Invest 2001; 108:117.</a></li><li><a class="nounderline abstract_t">Mancebo E, Moreno-Pelayo MA, Mencía A, et al. Gly111Ser mutation in CD8A gene causing CD8 immunodeficiency is found in Spanish Gypsies. Mol Immunol 2008; 45:479.</a></li><li><a class="nounderline abstract_t">Dumontet E, Osman J, Guillemont-Lambert N, et al. Recurrent Respiratory Infections Revealing CD8α Deficiency. J Clin Immunol 2015; 35:692.</a></li><li><a class="nounderline abstract_t">Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397:263.</a></li><li><a class="nounderline abstract_t">Xu H, Li X, Liu D, et al. Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility. Nature 2013; 496:523.</a></li><li><a class="nounderline abstract_t">McAdam AJ, Chang TT, Lumelsky AE, et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol 2000; 165:5035.</a></li><li><a class="nounderline abstract_t">Watanabe M, Hara Y, Tanabe K, et al. A distinct role for ICOS-mediated co-stimulatory signaling in CD4+ and CD8+ T cell subsets. Int Immunol 2005; 17:269.</a></li><li><a class="nounderline abstract_t">Schepp J, Chou J, Skrabl-Baumgartner A, et al. 14 Years after Discovery: Clinical Follow-up on 15 Patients with Inducible Co-Stimulator Deficiency. Front Immunol 2017; 8:964.</a></li><li><a class="nounderline abstract_t">Abolhassani H, El-Sherbiny YM, Arumugakani G, et al. Expanding Clinical Phenotype and Novel Insights into the Pathogenesis of ICOS Deficiency. J Clin Immunol 2020; 40:277.</a></li><li><a class="nounderline abstract_t">Kotlarz D, Ziętara N, Uzel G, et al. Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J Exp Med 2013; 210:433.</a></li><li><a class="nounderline abstract_t">Salzer E, Kansu A, Sic H, et al. Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency. J Allergy Clin Immunol 2014; 133:1651.</a></li><li><a class="nounderline abstract_t">Kotlarz D, Ziętara N, Milner JD, Klein C. Human IL-21 and IL-21R deficiencies: two novel entities of primary immunodeficiency. Curr Opin Pediatr 2014; 26:704.</a></li><li><a class="nounderline abstract_t">Edeer Karaca N, Özek G, Ataseven E, et al. Combined immunodeficiency with marginal zone lymphoma due to a novel homozygous mutation in IL-21R gene and successful treatment with hematopoietic stem cell transplantation. Pediatr Hematol Oncol 2021; 38:745.</a></li><li><a class="nounderline abstract_t">Cagdas D, Mayr D, Baris S, et al. Genomic Spectrum and Phenotypic Heterogeneity of Human IL-21 Receptor Deficiency. J Clin Immunol 2021; 41:1272.</a></li><li><a class="nounderline abstract_t">Stepensky P, Keller B, Abuzaitoun O, et al. Extending the clinical and immunological phenotype of human interleukin-21 receptor deficiency. Haematologica 2015; 100:e72.</a></li><li><a class="nounderline abstract_t">Dobbs K, Domínguez Conde C, Zhang SY, et al. Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections. N Engl J Med 2015; 372:2409.</a></li><li><a class="nounderline abstract_t">Moens L, Gouwy M, Bosch B, et al. Human DOCK2 Deficiency: Report of a Novel Mutation and Evidence for Neutrophil Dysfunction. J Clin Immunol 2019; 39:298.</a></li><li><a class="nounderline abstract_t">Alosaimi MF, Shendi H, Beano A, et al. T-cell mitochondrial dysfunction and lymphopenia in DOCK2-deficient patients. J Allergy Clin Immunol 2019; 144:306.</a></li><li><a class="nounderline abstract_t">Alizadeh Z, Mazinani M, Shakerian L, et al. DOCK2 Deficiency in a Patient with Hyper IgM Phenotype. J Clin Immunol 2018; 38:10.</a></li><li><a class="nounderline abstract_t">Sharifinejad N, Sadri H, Kalantari A, et al. First patient in the Iranian Registry with novel DOCK2 gene mutation, presenting with skeletal tuberculosis, and review of literature. Allergy Asthma Clin Immunol 2021; 17:126.</a></li><li><a class="nounderline abstract_t">Aytekin ES, Çağdaş D, Tan Ç, et al. Hematopoietic stem cell transplantation complicated with EBV associated hemophagocytic lymphohistiocytosis in a patient with DOCK2 deficiency. Turk J Pediatr 2021; 63:1072.</a></li><li><a class="nounderline abstract_t">Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 2009; 361:2046.</a></li><li><a class="nounderline abstract_t">Engelhardt KR, McGhee S, Winkler S, et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol 2009; 124:1289.</a></li><li><a class="nounderline abstract_t">Su HC. Dedicator of cytokinesis 8 (DOCK8) deficiency. Curr Opin Allergy Clin Immunol 2010; 10:515.</a></li><li><a class="nounderline abstract_t">Dinwiddie DL, Kingsmore SF, Caracciolo S, et al. Combined DOCK8 and CLEC7A mutations causing immunodeficiency in 3 brothers with diarrhea, eczema, and infections. J Allergy Clin Immunol 2013; 131:594.</a></li><li><a class="nounderline abstract_t">Alsum Z, Hawwari A, Alsmadi O, et al. Clinical, immunological and molecular characterization of DOCK8 and DOCK8-like deficient patients: single center experience of twenty-five patients. J Clin Immunol 2013; 33:55.</a></li><li><a class="nounderline abstract_t">Ruiz-García R, Lermo-Rojo S, Martínez-Lostao L, et al. A case of partial dedicator of cytokinesis 8 deficiency with altered effector phenotype and impaired CD8⁺ and natural killer cell cytotoxicity. J Allergy Clin Immunol 2014; 134:218.</a></li><li><a class="nounderline abstract_t">Purcell C, Cant A, Irvine AD. DOCK8 primary immunodeficiency syndrome. Lancet 2015; 386:982.</a></li><li><a class="nounderline abstract_t">Venegas-Montoya E, Staines-Boone AT, Sánchez-Sánchez LM, et al. Case Report: DOCK8 Deficiency Without Hyper-IgE in a Child With a Large Deletion. Front Pediatr 2021; 9:635322.</a></li><li><a class="nounderline abstract_t">Yousefnezhad S, Gharesouran J, Ghafouri-Fard S, et al. DOCK8-related Immunodeficiency Syndrome (DIDS): Report of Novel Mutations in Iranian Patients. J Mol Neurosci 2021; 71:2456.</a></li><li><a class="nounderline abstract_t">Momtazmanesh S, Rayzan E, Zoghi S, et al. Novel Variants of DOCK8 Deficiency in a Case Series of Iranian Patients. Endocr Metab Immune Disord Drug Targets 2022; 22:159.</a></li><li><a class="nounderline abstract_t">Tangye SG, Gray PE, Pillay BA, et al. Hyper-IgE Syndrome due to an Elusive Novel Intronic Homozygous Variant in DOCK8. J Clin Immunol 2022; 42:119.</a></li><li><a class="nounderline abstract_t">Zhang Q, Dove CG, Hor JL, et al. DOCK8 regulates lymphocyte shape integrity for skin antiviral immunity. J Exp Med 2014; 211:2549.</a></li><li><a class="nounderline abstract_t">Mizesko MC, Banerjee PP, Monaco-Shawver L, et al. Defective actin accumulation impairs human natural killer cell function in patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2013; 131:840.</a></li><li><a class="nounderline abstract_t">Randall KL, Chan SS, Ma CS, et al. DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. J Exp Med 2011; 208:2305.</a></li><li><a class="nounderline abstract_t">Janssen E, Morbach H, Ullas S, et al. Dedicator of cytokinesis 8-deficient patients have a breakdown in peripheral B-cell tolerance and defective regulatory T cells. J Allergy Clin Immunol 2014; 134:1365.</a></li><li><a class="nounderline abstract_t">Leiding JW, Holland SM. Warts and all: human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol 2012; 130:1030.</a></li><li><a class="nounderline abstract_t">Chu EY, Freeman AF, Jing H, et al. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol 2012; 148:79.</a></li><li><a class="nounderline abstract_t">Engelhardt KR, Gertz ME, Keles S, et al. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2015; 136:402.</a></li><li><a class="nounderline abstract_t">Aydin SE, Kilic SS, Aytekin C, et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients. J Clin Immunol 2015; 35:189.</a></li><li><a class="nounderline abstract_t">Haskologlu S, Kostel Bal S, Islamoglu C, et al. Clinical, immunological features and follow up of 20 patients with dedicator of cytokinesis 8 (DOCK8) deficiency. Pediatr Allergy Immunol 2020; 31:515.</a></li><li><a class="nounderline abstract_t">Kasap N, Celik V, Isik S, et al. A set of clinical and laboratory markers differentiates hyper-IgE syndrome from severe atopic dermatitis. Clin Immunol 2021; 223:108645.</a></li><li><a class="nounderline abstract_t">Pai SY, de Boer H, Massaad MJ, et al. Flow cytometry diagnosis of dedicator of cytokinesis 8 (DOCK8) deficiency. J Allergy Clin Immunol 2014; 134:221.</a></li><li><a class="nounderline abstract_t">Janssen E, Tsitsikov E, Al-Herz W, et al. Flow cytometry biomarkers distinguish DOCK8 deficiency from severe atopic dermatitis. Clin Immunol 2014; 150:220.</a></li><li><a class="nounderline abstract_t">Jing H, Zhang Q, Zhang Y, et al. Somatic reversion in dedicator of cytokinesis 8 immunodeficiency modulates disease phenotype. J Allergy Clin Immunol 2014; 133:1667.</a></li><li><a class="nounderline abstract_t">Pillay BA, Fusaro M, Gray PE, et al. Somatic reversion of pathogenic DOCK8 variants alters lymphocyte differentiation and function to effectively cure DOCK8 deficiency. J Clin Invest 2021; 131.</a></li><li><a class="nounderline abstract_t">Bittner TC, Pannicke U, Renner ED, et al. Successful long-term correction of autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency by hematopoietic stem cell transplantation. Klin Padiatr 2010; 222:351.</a></li><li><a class="nounderline abstract_t">Barlogis V, Galambrun C, Chambost H, et al. Successful allogeneic hematopoietic stem cell transplantation for DOCK8 deficiency. J Allergy Clin Immunol 2011; 128:420.</a></li><li><a class="nounderline abstract_t">Boztug H, Karitnig-Weiß C, Ausserer B, et al. Clinical and immunological correction of DOCK8 deficiency by allogeneic hematopoietic stem cell transplantation following a reduced toxicity conditioning regimen. Pediatr Hematol Oncol 2012; 29:585.</a></li><li><a class="nounderline abstract_t">Cuellar-Rodriguez J, Freeman AF, Grossman J, et al. Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency. Biol Blood Marrow Transplant 2015; 21:1037.</a></li><li><a class="nounderline abstract_t">Aydin SE, Freeman AF, Al-Herz W, et al. Hematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiency. J Allergy Clin Immunol Pract 2019; 7:848.</a></li><li><a class="nounderline abstract_t">Kuşkonmaz B, Ayvaz D, Tezcan İ, et al. Successful hematopoietic stem cell transplantation after myeloablative conditioning in three patients with dedicator of cytokinesis 8 deficiency (DOCK8) related Hyper IgE syndrome. Bone Marrow Transplant 2018; 53:339.</a></li><li><a class="nounderline abstract_t">Uygun DFK, Uygun V, Reisli İ, et al. Hematopoietic stem cell transplantation from unrelated donors in children with DOCK8 deficiency. Pediatr Transplant 2017; 21.</a></li><li><a class="nounderline abstract_t">Shah NN, Freeman AF, Su H, et al. Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for Dedicator-of-Cytokinesis 8 Deficiency Using Post-Transplantation Cyclophosphamide. Biol Blood Marrow Transplant 2017; 23:980.</a></li><li><a class="nounderline abstract_t">Raedler J, Magg T, Rohlfs M, et al. Lineage-Specific Chimerism and Outcome After Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency. J Clin Immunol 2021; 41:1536.</a></li><li><a class="nounderline abstract_t">Papan C, Hagl B, Heinz V, et al. Beneficial IFN-α treatment of tumorous herpes simplex blepharoconjunctivitis in dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2014; 133:1456.</a></li><li><a class="nounderline abstract_t">Keles S, Jabara HH, Reisli I, et al. Plasmacytoid dendritic cell depletion in DOCK8 deficiency: rescue of severe herpetic infections with IFN-α 2b therapy. J Allergy Clin Immunol 2014; 133:1753.</a></li><li><a class="nounderline abstract_t">Al-Zahrani D, Raddadi A, Massaad M, et al. Successful interferon-alpha 2b therapy for unremitting warts in a patient with DOCK8 deficiency. Clin Immunol 2014; 153:104.</a></li><li><a class="nounderline abstract_t">Ollech A, Mashiah J, Lev A, et al. Treatment options for DOCK8 deficiency-related severe dermatitis. J Dermatol 2021; 48:1386.</a></li><li><a class="nounderline abstract_t">Calzoni E, Platt CD, Keles S, et al. F-BAR domain only protein 1 (FCHO1) deficiency is a novel cause of combined immune deficiency in human subjects. J Allergy Clin Immunol 2019; 143:2317.</a></li><li><a class="nounderline abstract_t">Łyszkiewicz M, Ziętara N, Frey L, et al. Human FCHO1 deficiency reveals role for clathrin-mediated endocytosis in development and function of T cells. Nat Commun 2020; 11:1031.</a></li><li><a class="nounderline abstract_t">Lagresle-Peyrou C, Luce S, Ouchani F, et al. X-linked primary immunodeficiency associated with hemizygous mutations in the moesin (MSN) gene. J Allergy Clin Immunol 2016; 138:1681.</a></li><li><a class="nounderline abstract_t">Delmonte OM, Biggs CM, Hayward A, et al. First Case of X-Linked Moesin Deficiency Identified After Newborn Screening for SCID. J Clin Immunol 2017; 37:336.</a></li><li><a class="nounderline abstract_t">Henrickson SE, Andre-Schmutz I, Lagresle-Peyrou C, et al. Hematopoietic Stem Cell Transplant for the Treatment of X-MAID. Front Pediatr 2019; 7:170.</a></li><li><a class="nounderline abstract_t">Kovács AL, Kárteszi J, Prohászka Z, et al. Hemizygous nonsense variant in the moesin gene (MSN) leads to a new autoimmune phenotype of Immunodeficiency 50. Front Immunol 2022; 13:919411.</a></li><li><a class="nounderline abstract_t">Turvey SE, Durandy A, Fischer A, et al. The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency. J Allergy Clin Immunol 2014; 134:276.</a></li><li><a class="nounderline abstract_t">Torres JM, Martinez-Barricarte R, García-Gómez S, et al. Inherited BCL10 deficiency impairs hematopoietic and nonhematopoietic immunity. J Clin Invest 2014; 124:5239.</a></li><li><a class="nounderline abstract_t">Van Den Rym A, Taur P, Martinez-Barricarte R, et al. Human BCL10 Deficiency due to Homozygosity for a Rare Allele. J Clin Immunol 2020; 40:388.</a></li><li><a class="nounderline abstract_t">Garcia-Solis B, Van Den Rym A, Pérez-Caraballo JJ, et al. Clinical and Immunological Features of Human BCL10 Deficiency. Front Immunol 2021; 12:786572.</a></li><li><a class="nounderline abstract_t">Caruana G. Genetic studies define MAGUK proteins as regulators of epithelial cell polarity. Int J Dev Biol 2002; 46:511.</a></li><li><a class="nounderline abstract_t">Jun JE, Wilson LE, Vinuesa CG, et al. Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis. Immunity 2003; 18:751.</a></li><li><a class="nounderline abstract_t">Pérez de Diego R, Sánchez-Ramón S, López-Collazo E, et al. Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity. J Allergy Clin Immunol 2015; 136:1139.</a></li><li><a class="nounderline abstract_t">Stepensky P, Keller B, Buchta M, et al. Deficiency of caspase recruitment domain family, member 11 (CARD11), causes profound combined immunodeficiency in human subjects. J Allergy Clin Immunol 2013; 131:477.</a></li><li><a class="nounderline abstract_t">Greil J, Rausch T, Giese T, et al. Whole-exome sequencing links caspase recruitment domain 11 (CARD11) inactivation to severe combined immunodeficiency. J Allergy Clin Immunol 2013; 131:1376.</a></li><li><a class="nounderline abstract_t">Fuchs S, Rensing-Ehl A, Pannicke U, et al. Omenn syndrome associated with a functional reversion due to a somatic second-site mutation in CARD11 deficiency. Blood 2015; 126:1658.</a></li><li><a class="nounderline abstract_t">Lu HY, Sharma M, Sharma AA, et al. Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency. J Allergy Clin Immunol 2021; 148:1559.</a></li><li><a class="nounderline abstract_t">Dadi H, Jones TA, Merico D, et al. Combined immunodeficiency and atopy caused by a dominant negative mutation in caspase activation and recruitment domain family member 11 (CARD11). J Allergy Clin Immunol 2018; 141:1818.</a></li><li><a class="nounderline abstract_t">Urdinez L, Erra L, Palma AM, et al. Expanding spectrum, intrafamilial diversity, and therapeutic challenges from 15 patients with heterozygous CARD11-associated diseases: A single center experience. Front Immunol 2022; 13:1020927.</a></li><li><a class="nounderline abstract_t">McKinnon ML, Rozmus J, Fung SY, et al. Combined immunodeficiency associated with homozygous MALT1 mutations. J Allergy Clin Immunol 2014; 133:1458.</a></li><li><a class="nounderline abstract_t">Jabara HH, Ohsumi T, Chou J, et al. A homozygous mucosa-associated lymphoid tissue 1 (MALT1) mutation in a family with combined immunodeficiency. J Allergy Clin Immunol 2013; 132:151.</a></li><li><a class="nounderline abstract_t">Punwani D, Wang H, Chan AY, et al. Combined immunodeficiency due to MALT1 mutations, treated by hematopoietic cell transplantation. J Clin Immunol 2015; 35:135.</a></li><li><a class="nounderline abstract_t">Charbit-Henrion F, Jeverica AK, Bègue B, et al. Deficiency in Mucosa-associated Lymphoid Tissue Lymphoma Translocation 1: A Novel Cause of IPEX-Like Syndrome. J Pediatr Gastroenterol Nutr 2017; 64:378.</a></li><li><a class="nounderline abstract_t">Wiegmann H, Reunert J, Metze D, et al. Refining the dermatological spectrum in primary immunodeficiency: mucosa-associated lymphoid tissue lymphoma translocation protein 1 deficiency mimicking Netherton/Omenn syndromes. Br J Dermatol 2020; 182:202.</a></li><li><a class="nounderline abstract_t">Frizinsky S, Rechavi E, Barel O, et al. Novel MALT1 Mutation Linked to Immunodeficiency, Immune Dysregulation, and an Abnormal T Cell Receptor Repertoire. J Clin Immunol 2019; 39:401.</a></li><li><a class="nounderline abstract_t">Sefer AP, Abolhassani H, Ober F, et al. Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency. J Clin Immunol 2022; 42:634.</a></li><li><a class="nounderline abstract_t">Sonoda M, Ishimura M, Eguchi K, et al. Progressive B cell depletion in human MALT1 deficiency. Clin Exp Immunol 2021; 206:237.</a></li><li><a class="nounderline abstract_t">Rozmus J, McDonald R, Fung SY, et al. Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation. Clin Immunol 2016; 168:1.</a></li><li><a class="nounderline abstract_t">Beaussant-Cohen S, Jaber F, Massaad MJ, et al. Combined immunodeficiency in a patient with c-Rel deficiency. J Allergy Clin Immunol 2019; 144:606.</a></li><li><a class="nounderline abstract_t">Lévy R, Langlais D, Béziat V, et al. Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents. J Clin Invest 2021; 131.</a></li><li><a class="nounderline abstract_t">Vicioso Y, Wong DP, Roy NK, et al. NF-κB c-Rel Is Dispensable for the Development but Is Required for the Cytotoxic Function of NK Cells. Front Immunol 2021; 12:652786.</a></li><li><a class="nounderline abstract_t">Boutboul D, Kuehn HS, Van de Wyngaert Z, et al. Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency. J Clin Invest 2018; 128:3071.</a></li><li><a class="nounderline abstract_t">Tang S, Shen H, Qu C, et al. Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes. Bone Marrow Transplant 2019; 54:236.</a></li><li><a class="nounderline abstract_t">Kuehn HS, Nunes-Santos CJ, Rosenzweig SD. Germline IKZF1 mutations and their impact on immunity: IKAROS-associated diseases and pathophysiology. Expert Rev Clin Immunol 2021; 17:407.</a></li><li><a class="nounderline abstract_t">Kellner ES, Krupski C, Kuehn HS, et al. Allogeneic hematopoietic stem cell transplant outcomes for patients with dominant negative IKZF1/IKAROS mutations. J Allergy Clin Immunol 2019; 144:339.</a></li><li><a class="nounderline abstract_t">Hetemäki I, Kaustio M, Kinnunen M, et al. Loss-of-function mutation in IKZF2 leads to immunodeficiency with dysregulated germinal center reactions and reduction of MAIT cells. Sci Immunol 2021; 6:eabe3454.</a></li><li><a class="nounderline abstract_t">Shahin T, Kuehn HS, Shoeb MR, et al. Germline biallelic mutation affecting the transcription factor Helios causes pleiotropic defects of immunity. Sci Immunol 2021; 6:eabe3981.</a></li><li><a class="nounderline abstract_t">Hadjadj J, Aladjidi N, Fernandes H, et al. Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. Blood 2019; 134:9.</a></li><li><a class="nounderline abstract_t">Shahin T, Mayr D, Shoeb MR, et al. Identification of germline monoallelic mutations in IKZF2 in patients with immune dysregulation. Blood Adv 2022; 6:2444.</a></li><li><a class="nounderline abstract_t">Yamashita M, Kuehn HS, Okuyama K, et al. A variant in human AIOLOS impairs adaptive immunity by interfering with IKAROS. Nat Immunol 2021; 22:893.</a></li><li><a class="nounderline abstract_t">Kuehn HS, Chang J, Yamashita M, et al. T and B cell abnormalities, pneumocystis pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients. J Exp Med 2021; 218.</a></li><li><a class="nounderline abstract_t">Pannicke U, Baumann B, Fuchs S, et al. Deficiency of innate and acquired immunity caused by an IKBKB mutation. N Engl J Med 2013; 369:2504.</a></li><li><a class="nounderline abstract_t">Mousallem T, Yang J, Urban TJ, et al. A nonsense mutation in IKBKB causes combined immunodeficiency. Blood 2014; 124:2046.</a></li><li><a class="nounderline abstract_t">Alsum Z, AlZahrani MS, Al-Mousa H, et al. Multiple Family Members With Delayed Cord Separtion and Combined Immunodeficiency With Novel Mutation in IKBKB. Front Pediatr 2020; 8:9.</a></li><li><a class="nounderline abstract_t">Cuvelier GDE, Rubin TS, Junker A, et al. Clinical presentation, immunologic features, and hematopoietic stem cell transplant outcomes for IKBKB immune deficiency. Clin Immunol 2019; 205:138.</a></li><li><a class="nounderline abstract_t">Willmann KL, Klaver S, Doğu F, et al. Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nat Commun 2014; 5:5360.</a></li><li><a class="nounderline abstract_t">Conde CD, Petronczki ÖY, Baris S, et al. Polymerase δ deficiency causes syndromic immunodeficiency with replicative stress. J Clin Invest 2019; 129:4194.</a></li><li><a class="nounderline abstract_t">Cui Y, Keles S, Charbonnier LM, et al. Combined immunodeficiency caused by a loss-of-function mutation in DNA polymerase delta 1. J Allergy Clin Immunol 2020; 145:391.</a></li><li><a class="nounderline abstract_t">Mantravadi V, Bednarski JJ, Ritter MA, et al. Immunological Findings and Clinical Outcomes of Infants With Positive Newborn Screening for Severe Combined Immunodeficiency From a Tertiary Care Center in the U.S. Front Immunol 2021; 12:734096.</a></li><li><a class="nounderline abstract_t">Jabara HH, Boyden SE, Chou J, et al. A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency. Nat Genet 2016; 48:74.</a></li><li><a class="nounderline abstract_t">Aljohani AH, Al-Mousa H, Arnaout R, et al. Clinical and Immunological Characterization of Combined Immunodeficiency Due to TFRC Mutation in Eight Patients. J Clin Immunol 2020; 40:1103.</a></li><li><a class="nounderline abstract_t">Whangbo JS, Chou J, Al-Dhekri H, et al. Hematopoietic Stem Cell Transplantation Is a Curative Therapy for Transferrin Receptor 1 (TFRC) Deficiency. J Allergy Clin Immunol Pract 2021; 9:753.</a></li></ol></div><div id="topicVersionRevision">Topic 141326 Version 2.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35748970" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11435463" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Familial CD8 deficiency due to a mutation in the CD8 alpha gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17658607" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Gly111Ser mutation in CD8A gene causing CD8 immunodeficiency is found in Spanish Gypsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26563160" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Recurrent Respiratory Infections Revealing CD8αDeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9930702" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23619696" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11046032" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668466" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A distinct role for ICOS-mediated co-stimulatory signaling in CD4+ and CD8+ T cell subsets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28861081" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : 14 Years after Discovery: Clinical Follow-up on 15 Patients with Inducible Co-Stimulator Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31858365" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Expanding Clinical Phenotype and Novel Insights into the Pathogenesis of ICOS Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440042" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24746753" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25321844" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Human IL-21 and IL-21R deficiencies: two novel entities of primary immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33966600" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Combined immunodeficiency with marginal zone lymphoma due to a novel homozygous mutation in IL-21R gene and successful treatment with hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33929673" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Genomic Spectrum and Phenotypic Heterogeneity of Human IL-21 Receptor Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25398835" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Extending the clinical and immunological phenotype of human interleukin-21 receptor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26083206" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30838481" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Human DOCK2 Deficiency: Report of a Novel Mutation and Evidence for Neutrophil Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30826364" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : T-cell mitochondrial dysfunction and lymphopenia in DOCK2-deficient patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29204803" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : DOCK2 Deficiency in a Patient with Hyper IgM Phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34872585" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : First patient in the Iranian Registry with novel DOCK2 gene mutation, presenting with skeletal tuberculosis, and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35023658" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hematopoietic stem cell transplantation complicated with EBV associated hemophagocytic lymphohistiocytosis in a patient with DOCK2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19776401" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Combined immunodeficiency associated with DOCK8 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20004785" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20864884" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Dedicator of cytokinesis 8 (DOCK8) deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23374272" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Combined DOCK8 and CLEC7A mutations causing immunodeficiency in 3 brothers with diarrhea, eczema, and infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22968740" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical, immunological and molecular characterization of DOCK8 and DOCK8-like deficient patients: single center experience of twenty-five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24636087" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A case of partial dedicator of cytokinesis 8 deficiency with altered effector phenotype and impaired CD8⁺and natural killer cell cytotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25798541" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : DOCK8 primary immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34195158" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Case Report: DOCK8 Deficiency Without Hyper-IgE in a Child With a Large Deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33948880" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : DOCK8-related Immunodeficiency Syndrome (DIDS): Report of Novel Mutations in Iranian Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33634762" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Novel Variants of DOCK8 Deficiency in a Case Series of Iranian Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34657245" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hyper-IgE Syndrome due to an Elusive Novel Intronic Homozygous Variant in DOCK8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422492" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : DOCK8 regulates lymphocyte shape integrity for skin antiviral immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23380217" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Defective actin accumulation impairs human natural killer cell function in patients with dedicator of cytokinesis 8 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22006977" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25218284" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Dedicator of cytokinesis 8-deficient patients have a breakdown in peripheral B-cell tolerance and defective regulatory T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23036745" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Warts and all: human papillomavirus in primary immunodeficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21931011" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cutaneous manifestations of DOCK8 deficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25724123" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25627830" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32108967" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical, immunological features and follow up of 20 patients with dedicator of cytokinesis 8 (DOCK8) deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301882" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A set of clinical and laboratory markers differentiates hyper-IgE syndrome from severe atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24698323" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Flow cytometry diagnosis of dedicator of cytokinesis 8 (DOCK8) deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24440647" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Flow cytometry biomarkers distinguish DOCK8 deficiency from severe atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797421" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Somatic reversion in dedicator of cytokinesis 8 immunodeficiency modulates disease phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33290277" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Somatic reversion of pathogenic DOCK8 variants alters lymphocyte differentiation and function to effectively cure DOCK8 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21058221" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Successful long-term correction of autosomal recessive hyper-IgE syndrome due to DOCK8 deficiency by hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21546070" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Successful allogeneic hematopoietic stem cell transplantation for DOCK8 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22897717" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical and immunological correction of DOCK8 deficiency by allogeneic hematopoietic stem cell transplantation following a reduced toxicity conditioning regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25636378" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30391550" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hematopoietic Stem Cell Transplantation as Treatment for Patients with DOCK8 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29269803" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Successful hematopoietic stem cell transplantation after myeloablative conditioning in three patients with dedicator of cytokinesis 8 deficiency (DOCK8) related Hyper IgE syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28664550" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hematopoietic stem cell transplantation from unrelated donors in children with DOCK8 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28288951" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for Dedicator-of-Cytokinesis 8 Deficiency Using Post-Transplantation Cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34080085" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Lineage-Specific Chimerism and Outcome After Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24698314" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Beneficial IFN-αtreatment of tumorous herpes simplex blepharoconjunctivitis in dedicator of cytokinesis 8 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24767873" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Plasmacytoid dendritic cell depletion in DOCK8 deficiency: rescue of severe herpetic infections with IFN-α2b therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24743019" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Successful interferon-alpha 2b therapy for unremitting warts in a patient with DOCK8 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34043252" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment options for DOCK8 deficiency-related severe dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30822429" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : F-BAR domain only protein 1 (FCHO1) deficiency is a novel cause of combined immune deficiency in human subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32098969" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Human FCHO1 deficiency reveals role for clathrin-mediated endocytosis in development and function of T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27405666" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : X-linked primary immunodeficiency associated with hemizygous mutations in the moesin (MSN) gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28378256" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : First Case of X-Linked Moesin Deficiency Identified After Newborn Screening for SCID.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31139601" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hematopoietic Stem Cell Transplant for the Treatment of X-MAID.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36119109" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hemizygous nonsense variant in the moesin gene (MSN) leads to a new autoimmune phenotype of Immunodeficiency 50.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25087226" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25365219" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Inherited BCL10 deficiency impairs hematopoietic and nonhematopoietic immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32008135" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Human BCL10 Deficiency due to Homozygosity for a Rare Allele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34868072" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Clinical and Immunological Features of Human BCL10 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12141438" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Genetic studies define MAGUK proteins as regulators of epithelial cell polarity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12818157" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26277595" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23374270" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Deficiency of caspase recruitment domain family, member 11 (CARD11), causes profound combined immunodeficiency in human subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23561803" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Whole-exome sequencing links caspase recruitment domain 11 (CARD11) inactivation to severe combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26289640" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Omenn syndrome associated with a functional reversion due to a somatic second-site mutation in CARD11 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33872653" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28826773" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Combined immunodeficiency and atopy caused by a dominant negative mutation in caspase activation and recruitment domain family member 11 (CARD11).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36405754" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Expanding spectrum, intrafamilial diversity, and therapeutic challenges from 15 patients with heterozygous CARD11-associated diseases: A single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24332264" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Combined immunodeficiency associated with homozygous MALT1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23727036" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A homozygous mucosa-associated lymphoid tissue 1 (MALT1) mutation in a family with combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25627829" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Combined immunodeficiency due to MALT1 mutations, treated by hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27253662" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Deficiency in Mucosa-associated Lymphoid Tissue Lymphoma Translocation 1: A Novel Cause of IPEX-Like Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31049936" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Refining the dermatological spectrum in primary immunodeficiency: mucosa-associated lymphoid tissue lymphoma translocation protein 1 deficiency mimicking Netherton/Omenn syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31037583" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Novel MALT1 Mutation Linked to Immunodeficiency, Immune Dysregulation, and an Abnormal T Cell Receptor Repertoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35079916" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34559885" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Progressive B cell depletion in human MALT1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27109639" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31103457" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Combined immunodeficiency in a patient with c-Rel deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34623332" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33995369" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : NF-κB c-Rel Is Dispensable for the Development but Is Required for the Cytotoxic Function of NK Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889099" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29942002" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33691560" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Germline IKZF1 mutations and their impact on immunity: IKAROS-associated diseases and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30965037" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Allogeneic hematopoietic stem cell transplant outcomes for patients with dominant negative IKZF1/IKAROS mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34826260" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Loss-of-function mutation in IKZF2 leads to immunodeficiency with dysregulated germinal center reactions and reduction of MAIT cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34826259" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Germline biallelic mutation affecting the transcription factor Helios causes pleiotropic defects of immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30940614" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34920454" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Identification of germline monoallelic mutations in IKZF2 in patients with immune dysregulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34155405" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A variant in human AIOLOS impairs adaptive immunity by interfering with IKAROS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34694366" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : T and B cell abnormalities, pneumocystis pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24369075" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Deficiency of innate and acquired immunity caused by an IKBKB mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25139357" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A nonsense mutation in IKBKB causes combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32117824" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Multiple Family Members With Delayed Cord Separtion and Combined Immunodeficiency With Novel Mutation in IKBKB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30391351" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Clinical presentation, immunologic features, and hematopoietic stem cell transplant outcomes for IKBKB immune deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25406581" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31449058" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Polymeraseδdeficiency causes syndromic immunodeficiency with replicative stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31629014" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Combined immunodeficiency caused by a loss-of-function mutation in DNA polymerase delta 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34539671" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Immunological Findings and Clinical Outcomes of Infants With Positive Newborn Screening for Severe Combined Immunodeficiency From a Tertiary Care Center in the U.S.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26642240" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32851577" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Clinical and Immunological Characterization of Combined Immunodeficiency Due to TFRC Mutation in Eight Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33096268" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Hematopoietic Stem Cell Transplantation Is a Curative Therapy for Transferrin Receptor 1 (TFRC) Deficiency.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
